Anti-inflammatory drug found to help adults with severe schizophrenia
- Schizophrenia affects 35 million adults worldwide each year
- First study to find that monoclonal antibody drug can provide symptom relief to people with schizophrenia and inflammation
- Randomised control trial
- Opens pathways towards personalised treatment of schizophrenia
Research conducted at Neuroscience Research Australia has found that an injection of an anti-flammatory biological known as Canakinumab in patients with schizophrenia and elevated inflammation brought about a decrease in psychotic symptom severity and inflammation. The research was published in Brain, Behavior, and Immunity.
“Our study is the first clinical trial of anti-inflammatories for people with schizophrenia who also have an elevated inflammation status,” says Professor Cyndi Shannon Weickert, lead author on the study and Senior Professor at Neuroscience Research Australia.
Read more: Anti-inflammatory drug found to help adults with severe schizophrenia
Latest News & Events
Professor Matthew Kiernan AM awarded the 2024 GSK Award for Research Excellence
January 23, 2024Professor Matthew Kiernan AM, CEO and Institute Director at NeuRA and Scientia Professor of Neuroscience at UNSW, has won the prestigious 2024 GSK Award for Research Excellence for his work in neurodegenerative diseases.
Lived experience is the beating heart of mental health and suicide prevention
January 23, 2024Mental ill health and suicidal distress are deeply human experiences – which is why keeping people safe during these challenging times requires a human touch.
Stroke associated with long-term cognitive decline
January 23, 2024New evidence from the Centre for Healthy Brain Ageing (CHeBA) indicates that older adults who experience a stroke for the first time will have substantial immediate and accelerated long-term cognitive decline.
Mindgardens Neuroscience Network acknowledges the Traditional Owners of Country throughout Australia and recognises their continuing connection to land, waters and community. We pay our respect to them and their cultures, and to Elders past, present and emerging.
We acknowledge the voices of people with lived experience, their carers, families and kinship groups. We recognise the expertise acquired through living with a mental health, drug and alcohol or neurological disorder and acknowledge those who care for people on their recovery journey. We place lived experience at the heart of all that we do.
Brings together the strengths of four founding organisations
